Press Releases – CellCentric

Press and media

Press releases

More regular updates and key information, updates and news can be found through our tweets

cell-centric-expands-to-US-office-Boston

CellCentric Expands US Presence with New Office in Boston

2 April 2025 Press Release

CellCentric expands executive team with new Chief Strategy Officer

13 January 2025 Press Release

CellCentic Presents Latest Clinical Data at ASH: Promising Efficacy and Safety in Multiple Myeloma

10 December 2024 Press Release

CellCentric to Share Latest Inobrodib Phase II Data; Oral Presentation at ASH 2024

6 November 2024 Press Release

CellCentric expands executive team with new Chief Development Officer

4 September 2024 Press Release

CellCentric Secures $35 Million Investment from RA Capital Management

24 July 2024 Press Release

CellCentric discloses significant new clinical data, demonstrating inobrodib’s efficacy in ongoing Phase I/IIa clinical trials

11 December 2023 Press Release

Inobrodib’s novel mechanism: new data published in Cancer Cell

22 November 2023 Press Release

CellCentric secures further investment from BrightEdge, the American Cancer Society’s impact investment and innovation arm

12 September 2023 Press Release

CellCentric announces $25m strategic investment from Pfizer

11 July 2023 Press Release

CellCentric Granted FDA Orphan Drug Designation for Inobrodib (CCS1477) for the Treatment of Multiple Myeloma

29 June 2023 Press Release

CellCentric receives FDA Fast Track designation for inobrodib for the treatment of patients with relapsed refractory multiple myeloma

13 June 2023 Press Release

Inobrodib

A first-in-class oral
anti-cancer drug